Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.
Carolyn TallonBenjamin J BellMedhinee M MalvankarPragney DemeCarlos Nogueras-OrtizErden ErenAjit G ThomasKristen R HollingerArindom PalMaja MustapicMeixiang HuangKaleem ColemanTawnjerae R JoeRana RaisNorman J HaugheyDimitrios KapogiannisBarbara S SlusherPublished in: Translational neurodegeneration (2023)
PDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice.